LCM
SYRE icon

Legato Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Legato Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,458
Closed -$435K – 624
2024
Q1 		$435K Buy
+11,458
New +$332K 0.05% 464

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Legato Capital Management's SYRE Position: Q2 2024 in Review

Legato Capital Management sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 11,458 shares — an estimated $435K sold.

Legato Capital Management first reported a position in SYRE in Q1 2024 and held it in 1 quarter. The position peaked at $435K in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • Legato Capital Management reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Legato Capital Management sold 11,458 Spyre Therapeutics shares in Q2 2024, an estimated $435K.
  • Legato Capital Management first reported a position in Spyre Therapeutics in Q1 2024 and held it in 1 quarter.
  • Legato Capital Management's Spyre Therapeutics position peaked at $435K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on Legato Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.